Last Updated : September 8, 2016
The number of drugs available for sedation of patients in the intensive care unit (ICU) is limited, with both benzodiazepines and propofol being commonly used.
Dexmedetomidine is a selective alpha-2 adrenergic agonist with sedative properties; it produces a pattern of sedation different from other drugs.
The choice of sedative drugs in the ICU setting is important, as the drug selected can affect patient outcomes, making their use an important formulary policy decision for acute-care hospitals. Decisions will be made from a quality of care and a budgetary perspective, as substantial cost differences exist between these drugs.
This project aims at assessing the cost-effectiveness of dexmedetomidine for the sedation of patients in the ICU. Findings will inform formulary decisions regarding the use of dexmedetomidine in Canadian regional health authorities and hospitals.
PUBLISHED: June 2017